Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/β-catenin pathway

Figure 4 Annexin A1 inhibits activation of RAW264. 7 cells and hepatic stellate cells. A: Changes in annexin A1 (AnxA1) expression in hepatocyte and hepatic stellate cells; B: Transforming growth factor-β1 mRNA expression; C: Interleukin (IL)-1β mRNA was quantified using quantitative real-time polymerase chain reaction; D: Changes in IL-6 mRNA in RAW264.7; E: Immunoblotting assay for the detection of AnxA1 in hepatocytes; F: Immunoblotting assay for AnxA1, α-smooth muscle actin (α-SMA) and β-catenin, lysates were analyzed with AnxA1, α-SMA or β-catenin antibody. GAPDH was used as an internal control. ^aP < 0.05, ^bP < 0.01 and ^cP < 0.001 vs controls; ^dP < 0.05 and ^eP < 0.01 vs lipopolysaccharide; ^fP < 0.05, ^gP < 0.01 and ^hP < 0.001 vs lipopolysaccharide + Ac2-26 (n = 8). AnxA1: Annexin A1; α-SMA: α-smooth muscle actin; HSC: Hepatic stellate cell; LPS: Lipopolysaccharide; TGF-β1: Transforming growth factor β1; HCs: Hepatocyte; IL: Interleukin; Ac2-26: Active N-terminal peptide of AnxA1; Boc2: N-formyl peptide receptor antagonist N-Boc-Phe-Leu-Phe-Leu-Phe.